Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.

Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
复制标题

DOI:
10.1007/s00280-009-1003-z
复制
发表时间:
2009-12
影响因子:
3
通讯作者:
Kris, Mark G.
Kris, Mark G.
中科院分区:
医学3区
文献类型:
--
作者:
Cassileth, Barrie R.;Rizvi, Naiyer;Deng, Gary;Yeung, K. Simon;Vickers, Andrew;Guillen, Stacey;Woo, Derek;Coleton, Marci;Kris, Mark G.

文献摘要

参考文献

被引文献

相似文献

研究先前发现对非小细胞肺癌(NSCLC)有效的常用黄芪草药配方对非小细胞肺癌患者多西他赛的药代动力学的影响。既往接受含铂化疗后进展的晚期NSCLC患者入选,接受多西他赛35 mg/m2治疗3周,随后停药1周。在第二次给药前4天,口服金复康。比较多西他赛首次给药(不含金复康)和第3次给药(含金复康)的药代动力学研究。入组的24例患者中,21例开始使用金复康和多西他赛。金复康对多西他赛的药代动力学无明显影响。至疾病进展或退出治疗的中位时间为7周。12例患者因疾病进展而退出研究; 9例患者退出研究。在本研究中,金复康未改变多西他赛的药代动力学,也未影响生存率。
To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC. Patients with advanced NSCLC who progressed after prior platinum-containing chemotherapy were accrued and received docetaxel at 35 mg/m2 for 3 weeks followed by 1 week of rest. At 4 days prior to the second dosing, Jinfukang was given orally. Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared. Of the 24 patients enrolled, 21 started Jinfukang and docetaxel. Jinfukang had no significant impact on the pharmacokinetics of docetaxel. Median time to progression or withdrawal from treatment was 7 weeks. Twelve patients were removed from study for progression of disease; nine patients withdrew. Jinfukang did not alter the pharmacokinetics of docetaxel nor appear to affect survival in this study.
DOI: 10.1007/s00228-006-0096-0
发表时间: 2006-03-01
影响因子: 2.9
作者:
Madabushi, R;Frank, B;Butterweck, V
通讯作者: Butterweck, V
DOI: 10.1378/chest.123.1_suppl.226s
发表时间: 2003-01-01
期刊: CHEST
影响因子: 9.6
作者:
Socinski, MA;Morris, DE;Lilenbaum, R
通讯作者: Lilenbaum, R
DOI: 10.1007/s002800100317
发表时间: 2001-08-01
影响因子: 3
作者:
Bhargava, P;Marshall, JL;Rizvi, NA
通讯作者: Rizvi, NA
DOI: 10.1200/jco.2005.03.6392
发表时间: 2006-01-20
影响因子: 45.3
作者:
McCulloch, M;See, C;Colford, JM
通讯作者: Colford, JM
DOI: 10.1634/theoncologist.11-7-742
发表时间: 2006-07-01
期刊: ONCOLOGIST
影响因子: 5.8
作者:
Meijerman, Irma;Beijnen, Jos H.;Schellens, Jan H. M.
通讯作者: Schellens, Jan H. M.